Lufax Holding Ltd vs Vaxcyte Inc. Common Stock — how do they compare? Lufax Holding Ltd trades at $0.85 (market cap $894.58M), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 11.7× Lufax Holding Ltd's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lufax Holding Ltd for 14 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| LU | PCVX | |
|---|---|---|
Market Cap | $894.58M | $10.51B |
Volume | 1,044,976 | 2,644,694 |
Sector | Financials | Health |
52-Week High | $3.64 | $73.82 |
52-Week Low | $0.86 | $40.32 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $58.66B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
Lufax Holding Ltd (LU) trades at $0.9201, down 0.47% on the day, reflecting ongoing challenges in China's consumer lending market. The stock shows a bearish technical signal with negative earnings trends, having missed EPS estimates for three consecutive quarters. Recent corporate actions include a 10:1 reverse stock split effective October 2026. Despite deep value metrics (P/S 0.24, P/B 0.07), the company reports negative net income margins and declining revenue, with 2025 showing a $2.10B loss on $23.11B revenue.
LU presents a high-risk opportunity with significant analyst divergence. While 69% of analysts rate it Buy citing deep valuation and Ping An backing, fundamental deterioration and regulatory headwinds create substantial downside risk. The stock's appeal rests on potential capital return catalysts rather than business turnaround, requiring careful risk assessment given China's tightening financial regulations and persistent operational losses.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →